 |
 Video: What is a Stock Split?
|
|
|
| Fennec Pharmaceuticals is a biopharmaceutical company focused on its product candidate, PEDMARK® (sodium thiosulfate injection), which is used to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors. Co. has established Fennec HEARS™, a single source program designed to connect PEDMARK® patients to both patient financial and product access support. The program provides assistance and resources, regardless of insurance type, that can address co-pays or lack of coverage when certain eligibility requirements are met. According to our Fennec Pharmaceuticals stock split history records, Fennec Pharmaceuticals has had 0 splits. | |
|
Fennec Pharmaceuticals (FENC) has 0 splits in our Fennec Pharmaceuticals stock split history database.
Looking at the Fennec Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Fennec Pharmaceuticals shares, starting with a $10,000 purchase of FENC, presented on a split-history-adjusted basis factoring in the complete Fennec Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
09/18/2017 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$11.37 |
|
| End price/share: |
$9.21 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-18.96% |
|
| Average Annual Total Return: |
-3.13% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$8,104.68 |
|
| Years: |
6.61 |
|
|
|
|
|
